Brink Therapeutics develops next-generation recombinase enzymes designed for ultra-precise and efficient gene editing. These enzymes aim to enable large-scale production of cell and gene therapies for treating cancer and genetic disorders.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current gene-editing technologies, such as CRISPR-Cas9, can cause unintended double-strand breaks in DNA, raising safety concerns and limiting their potential for widespread therapeutic applications. Existing methods may also lack the precision and efficiency required for large-scale production of cell and gene therapies.
Solution
Brink Therapeutics is developing a new generation of site-specific recombinase enzymes that enable precise DNA modifications—such as inserting, removing, or inverting DNA sequences—without causing double-strand breaks. These enzymes offer a safer, more precise alternative to existing technologies like CRISPR-Cas9, giving them the potential to revolutionize Cell and Gene Therapies and finally push them over the brink of mass accessibility. The company uses advanced Directed Evolution, deep gene-mining techniques and AI to unlock new possibilities for treating & curing cancers, autoimmune diseases, genetic disorders and beyond. Brink's technology aims to facilitate the large-scale production of cell and gene therapies with improved safety and efficacy.
Target Audience
The primary target audience includes cell and gene therapy manufacturers, pharmaceutical companies, and research institutions focused on developing treatments for cancer, autoimmune diseases, and genetic disorders.
Features
- Site-specific recombinases for precise gene editing
- DNA modification without double-strand breaks
- Safer alternative to CRISPR-Cas9 technology
- Utilizes Directed Evolution, deep gene-mining techniques and AI
- Potential for large-scale production of cell and gene therapies